ORLANDO, Fla. — Star Therapeutics said its once-a-month injection for von Willebrand disease substantially cut bleeding rates in a preliminary study, and is thinking about the next moves to complete a larger trial and eventually get the drug to patients. The trial data released Saturday looked at eight patients, and showed that treatment with Star’s shot decreased bleeds by a median of 81%...

ORLANDO, Fla. — With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its anti-bleeding antibody VGA039. In a phase 1/2 trial in von Willebrand disease (VWD), the molecule substantially reduced bleeding in eight patients. “We're seeing significant reductions in bleeds across all types of VWD and all types of bleeds,” Star founder...

Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator.

Star Therapeutics patched together a $125 million Series D in what it thinks is pharma’s next big therapeutic category. The South San Francisco startup expects the funds to add a few years of runway and get its sole clinical-stage drug most of the way through a Phase 3 trial in von Willebrand disease while also expanding into other disorders, CEO Adam Rosenthal told Endpoints News...

The biotech began Phase 3 testing of an experimental medicine for Von Willebrand disease in early September. Star Therapeutics has raised $125 million in new venture funding that will help propel its experimental blood disease drug through late-stage testing. Initially formed as a “hub-and-spoke” biotech intending to build single-drug offshoots, Star is now primarily focused on a singular program for...